Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oral administration of sucroferric oxyhydroxide during hemodialysis sessions against resistant hyperphosphatemia

Trial Profile

Oral administration of sucroferric oxyhydroxide during hemodialysis sessions against resistant hyperphosphatemia

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Feb 2018

At a glance

  • Drugs Sucroferric oxyhydroxide (Primary)
  • Indications Hyperphosphataemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top